Survey of Retail Prices: Payment and Utilization Rates, and Performance Rankings

ICR 201203-0938-002

OMB: 0938-1041

Federal Form Document

Forms and Documents
Document
Name
Status
Form and Instruction
Modified
Supplementary Document
2012-05-07
Supporting Statement B
2012-03-02
Supplementary Document
2012-03-02
Supplementary Document
2012-03-02
Supporting Statement A
2012-05-07
ICR Details
0938-1041 201203-0938-002
Historical Active 201103-0938-006
HHS/CMS
Survey of Retail Prices: Payment and Utilization Rates, and Performance Rankings
Revision of a currently approved collection   No
Regular
Approved with change 05/11/2012
Retrieve Notice of Action (NOA) 03/05/2012
Prior to renewal or revision of the NADAC survey, CMS must provide OMB with information on the quality of data obtained through this survey and any problems with pharmacy non-response.
  Inventory as of this Action Requested Previously Approved
05/31/2015 36 Months From Approved 05/31/2014
30,051 0 51
15,765 0 765
0 0 0

This revision request is for a survey of the average acquisition costs of all covered outpatient drugs purchased by retail community pharmacies. The prices will be updated on at least a monthly basis.

PL: Pub.L. 109 - 171 6001 Name of Law: Deficit Reduction Act
  
PL: Pub.L. 109 - 171 6001(f) Name of Law: Deficit Reduction Act

Not associated with rulemaking

  76 FR 60845 09/30/2011
77 FR 12847 03/02/2012
Yes

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 30,051 51 30,000 0 0 0
Annual Time Burden (Hours) 15,765 765 15,000 0 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No
This package is being revised to include a second survey tool to survey the pharmacies. This second survey is entitled "Survey of Retail Community Pharmacy Invoice Prices." CMS will also develop a National Average Drug Acquisition Cost (NADAC) for States to consider when developing reimbursement methodology. The NADAC is a new pricing benchmark that will be based on the national average costs that pharmacies pay to acquire Medicaid covered outpatient drugs. This pricing benchmark will be based on drug acquisition costs collected directly from pharmacies through a nationwide survey process. This survey will be conducted on a monthly basis to ensure that the NADAC reference file remains current and up-to-date.

$6,200,000
Yes Part B of Supporting Statement
No
No
No
No
Uncollected
Mitch Bryman 410 786-5258 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
03/05/2012


© 2024 OMB.report | Privacy Policy